Showing 5,981 - 6,000 results of 74,121 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (mean decrease)) ))', query time: 1.08s Refine Results
  1. 5981

    C2GnT1 gene knockdown decreases C2-O-sLe<sup>X</sup> glycoproteins and C2GnT1 activity. by Catherine A. St. Hill (357388)

    Published 2013
    “…Note the absence of a detected C2GnT1 protein 50 kDa band. (D) We observed a 30–40% decrease in reactivity with CHO-131 mAb by flow cytometry for LS174T and HepG2 cells that contained C2GnT1 shRNA. …”
  2. 5982
  3. 5983

    Design, Synthesis, and Biological Evaluation of Indoline and Indole Derivatives as Potent and Selective α<sub>1A</sub>-Adrenoceptor Antagonists by Fei Zhao (183673)

    Published 2016
    “…In this study, two highly selective and potent α<sub>1A</sub>-AR antagonists, compounds (<i>R</i>)-<b>14r</b> (IC<sub>50</sub> = 2.7 nM, α<sub>1B</sub>/α<sub>1A</sub> = 640.1, α<sub>1D</sub>/α<sub>1A</sub> = 408.2) and (<i>R</i>)-<b>23l</b> (IC<sub>50</sub> = 1.9 nM, α<sub>1B</sub>/α<sub>1A</sub> = 1506, α<sub>1D</sub>/α<sub>1A</sub> = 249.6), which exhibited similar activities and better selectivities in cell-based calcium assays as compared with the marketed drug silodosin (IC<sub>50</sub> = 1.9 nM, α<sub>1B</sub>/α<sub>1A</sub> = 285.9, α<sub>1D</sub>/α<sub>1A</sub> = 14.4), were identified. …”
  4. 5984
  5. 5985

    Supplementary Material for: Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50... by Catalá-López F. (4142920)

    Published 2014
    “…<b><i>Results:</i></b> The presence of CNS disorders was associated with a reduced co-occurrence of cancer (ES = 0.92; 95% confidence interval, CI: 0.87-0.98; I<sup>2</sup> = 94.5%). …”
  6. 5986
  7. 5987
  8. 5988

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
  9. 5989

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
  10. 5990
  11. 5991
  12. 5992
  13. 5993
  14. 5994
  15. 5995

    Supplementary table 1. by Javier A. Flores-Cohaila (16933983)

    Published 2025
    “…<div><p>Introduction</p><p>The prevalence of workplace violence in healthcare is 50–60%. While it has been linked to decreased job satisfaction, diminished quality of care, and economic burdens on healthcare systems, there are still major gaps. …”
  16. 5996
  17. 5997
  18. 5998

    Participant selection flowchart. by Javier A. Flores-Cohaila (16933983)

    Published 2025
    “…<div><p>Introduction</p><p>The prevalence of workplace violence in healthcare is 50–60%. While it has been linked to decreased job satisfaction, diminished quality of care, and economic burdens on healthcare systems, there are still major gaps. …”
  19. 5999
  20. 6000